Stock MPIT MEDICAL PROGNOSIS INSTITUTE A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
AQ
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
AQ
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
AQ
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
AQ
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
AQ
Allarity Therapeutics : Material Agreement - Form 8-K
PU
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
AQ
Allarity Therapeutics to Present at Biomarkers 2024
AQ
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
AQ
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic
AQ
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
AQ
Allarity Therapeutics to Present at Biomarkers Europe 2023
AQ
Allarity Therapeutics : Modification to Rights of Security Holders - Form 8-K
PU
Allarity Therapeutics : Material Agreement - Form 8-K
PU
PLOS ONE Publishes Data on Allarity Therapeutics DRP Companion Diagnostic for Dovitinib
AQ
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
AQ
Allarity Therapeutics : CEO Letter to Shareholders - Form 8-K
PU
Allarity Therapeutics : CEO Letter to Shareholders
PU
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. MPIT Stock
  5. News Medical Prognosis Institute A/S
  6. Press Releases